Hahn-Jun Lee, M.Sc., Ph.D.President / CEO
Dr. Lee is a serial entrepreneur who founded Polaryx® Therapeutics, Inc to develop patient-friendly oral medications for lysosomal storage disorders, such as Batten Disease, a devastating neurodegenerative pediatric genetic disorder. He founded Epygenix Therapeutics, Inc. to develop precision medicines for Dravet syndrome and other rare and intractable genetic epilepsies and Curyx Bio, Inc. to develop disease modifying medicines for Parkinson’s Disease, Huntington’s Disease, and Glycine Encephalopathy. He also founded Focus Therapeutics, L.L.C. to provide a catalytic role between US and Asian Pacific biotechnology, transactions, and partnerships.
He has extensive experience in R&D, deal making, business development, and has consulted for several top-notch health care Venture Capital firms, global pharma and biotech companies, including Doman Associates, Shire Human Genetic Therapies, P&G Pharma, Melior Discovery, and CDI. He has also consulted for many Korean biotechs, Venture Capital firms, and research institutes, such as Korea Research Institute of Chemical Technology (KRICT), CHA Biotech, and CMG Pharma.
Dr. Lee was an Assistant Professor of Biotechnology in the Department of Orthopedic Surgery, College of Physicians and Surgeons, Columbia University in the city of New York. He also worked as a Staff Scientist at the RIKEN Brain Science Institute in Japan.
He obtained his B.S. in Life Science from Sogang University, Seoul, Korea. He completed his M.S. and Ph.D. in applied biotechnology in the Department of Applied Biotechnology at the University of Tokyo, Japan.